Should I buy or sell UroGen Pharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" URGN shares. View URGN analyst ratings or view top-rated stocks .

What is UroGen Pharma's stock price target for 2024?

2 brokers have issued 1 year target prices for UroGen Pharma's shares. Their URGN share price targets range from $34.00 to $54.00. On average, they predict the company's stock price to reach $46.67 in the next year. This suggests a possible upside of 241.9% from the stock's current price. View analysts price targets for URGN or view top-rated stocks among Wall Street analysts .

How have URGN shares performed in 2024?

UroGen Pharma's stock was trading at $15.00 at the start of the year. Since then, URGN stock has decreased by 9.0% and is now trading at $13.65. View the best growth stocks for 2024 here .

When is UroGen Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our URGN earnings forecast .

How were UroGen Pharma's earnings last quarter?

UroGen Pharma Ltd. (NASDAQ:URGN) announced its quarterly earnings data on Thursday, March, 14th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by $0.05. The firm earned $23.53 million during the quarter, compared to the consensus estimate of $22.30 million.

What ETFs hold UroGen Pharma's stock?

ETFs with the largest weight of UroGen Pharma (NASDAQ:URGN) stock in their portfolio include ARK Israel Innovative Technology ETF (IZRL) . Amplify BlueStar Israel Technology ETF (ITEQ) .

What other stocks do shareholders of UroGen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE) , Micron Technology (MU) , OPKO Health (OPK) , TG Therapeutics (TGTX) , VBI Vaccines (VBIV) , Exelixis (EXEL) , (KITE) (KITE) , Syndax Pharmaceuticals (SNDX) , AbbVie (ABBV) and Aytu BioPharma (AYTU) .

When did UroGen Pharma IPO?

UroGen Pharma (URGN) raised $46 million in an IPO on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

How do I buy shares of UroGen Pharma?

Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:URGN

UroGen Pharma (URGN) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free URGN Stock Alerts

$13.51

-0.75 (-5.26%)

(As of 02:31 PM ET)

Compare

Today's Range: $13.46
▼
$14.28
50-Day Range: $12.95
▼
$19.33
52-Week Range: $8.69
▼
$24.13

Volume: 206,163 shs
Average Volume: 342,083 shs
Market Capitalization: $316.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $46.67

Get UroGen Pharma alerts:

UroGen Pharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 241.9% Upside
$46.67 Price Target
Short Interest: Bearish
17.87% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.33
Upright™ Environmental Score
News Sentiment: 0.40
Based on 7 Articles This Week
Insider Trading: Selling Shares
$306,829 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.59) to ($1.75) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.03 out of 5 stars

Medical Sector

167th out of 918 stocks

Pharmaceutical Preparations Industry

61st out of 419 stocks

3.5

Analyst's Opinion

Consensus Rating
UroGen Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
UroGen Pharma has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
17.87% of the outstanding shares of UroGen Pharma have been sold short.
Short Interest Ratio / Days to Cover
UroGen Pharma has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.
Change versus previous month
Short interest in UroGen Pharma has recently decreased by 1.41%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
UroGen Pharma does not currently pay a dividend.
Dividend Growth
UroGen Pharma does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
UroGen Pharma has received a 70.26% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Other cancer medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for UroGen Pharma is -1.33.

2.4

News and Social Media Coverage

News Sentiment
UroGen Pharma has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for UroGen Pharma this week, compared to 2 articles on an average week.
Search Interest
3 people have searched for URGN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added UroGen Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, UroGen Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $306,829.00 in company stock.
Percentage Held by Insiders
11.13% of the stock of UroGen Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
91.29% of the stock of UroGen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for UroGen Pharma are expected to grow in the coming year, from ($3.59) to ($1.75) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of UroGen Pharma is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of UroGen Pharma is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About UroGen Pharma Stock (NASDAQ:URGN)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

URGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

URGN Stock News Headlines

March 22, 2024 | insidertrades.com

UroGen Pharma Ltd. (NASDAQ:URGN) Insider Sells $168,600.00 in Stock

April 18, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Urogen Pharma Amid Promising Clinical Data and Strategic Conference Presentations

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

April 17, 2024 | businesswire.com

UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers

April 16, 2024 | investing.com

UroGen's UGN-103 advances to Phase 3 for bladder cancer

April 15, 2024 | businesswire.com

UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

April 14, 2024 | finance.yahoo.com

UroGen Pharma Ltd.'s (NASDAQ:URGN) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week

April 4, 2024 | markets.businessinsider.com

Urogen Pharma’s Strategic Defense and Pipeline Progress Bolster Buy Rating

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

March 18, 2024 | seekingalpha.com

UroGen: All Eyes On UGN-102

March 17, 2024 | finance.yahoo.com

UroGen Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line

March 15, 2024 | finance.yahoo.com

UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcript

March 14, 2024 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Urogen Pharma (URGN) and Cullinan Management (CGEM)

March 14, 2024 | finanznachrichten.de

UroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102

March 14, 2024 | finance.yahoo.com

UroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challenges

March 14, 2024 | investorplace.com

URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023

March 14, 2024 | finance.yahoo.com

UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102

March 13, 2024 | markets.businessinsider.com

UroGen Pharma earnings preview: what to expect

March 8, 2024 | businesswire.com

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 4, 2024 | finance.yahoo.com

UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024

March 1, 2024 | stocknews.com

3 Biotech Stocks Climbing the Ranks to Watch

March 1, 2024 | msn.com

UroGen falls as Teva seeks FDA nod for Jelmyto generic

February 26, 2024 | businesswire.com

UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference

February 19, 2024 | finance.yahoo.com

URGN Mar 2024 22.500 call

February 17, 2024 | finance.yahoo.com

URGN Mar 2024 17.500 call

February 17, 2024 | finance.yahoo.com

URGN Mar 2024 10.000 put

February 8, 2024 | msn.com

UroGen Pharma Shares Insights at Guggenheim Healthcare Talks

See More Headlines

Receive URGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:URGN
CUSIP: N/A
CIK: 1668243
Web: www.urogen.com
Phone: (646) 768-9780
Fax: N/A
Employees: 198
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $46.67
High Stock Price Target: $54.00
Low Stock Price Target: $34.00
Potential Upside/Downside: +227.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.73)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-102,240,000.00
Net Margins: -123.61%
Pretax Margin: -118.87%
Return on Equity: N/A
Return on Assets: -70.48%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.42
Quick Ratio: 5.24

Sales & Book Value

Annual Sales: $82.71 million
Price / Sales: 4.04
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($2.78) per share
Price / Book: -5.13

Miscellaneous

Outstanding Shares: 23,450,000
Free Float: 20,844,000
Market Cap: $334.40 million
Optionable: Optionable
Beta: 1.07

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Ms. Elizabeth A. Barrett (Age 62)
President, CEO & Director
Comp: $1.12M
Mr. Dong Kim (Age 47)
Chief Financial Officer
Comp: $546.68k
Mr. Jason Drew Smith (Age 52)
General Counsel, Chief Compliance Officer & Corporate Secretary
Comp: $717.58k
Vincent I. Perrone
Senior Director of Investor Relations
Mr. Bryon Wornson
Executive Vice President of Talent, Advocacy & Communications
Dr. Sari Prutchi-Sagiv Ph.D.
Marketing Director
Dr. Marina Konorty
Executive Vice President of Research & Development and Technical Operations
Dr. Mark P. Schoenberg M.D. (Age 66)
Chief Medical Officer
Comp: $579.5k
Mr. Jeffrey Bova M.B.A.
Chief Commercial Officer
Mr. James Ottinger R.ph.
Executive Vice President of Regulatory Affairs & Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

URGN Stock Analysis - Frequently Asked Questions

Should I buy or sell UroGen Pharma stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" URGN shares.
View URGN analyst ratings or view top-rated stocks.
What is UroGen Pharma's stock price target for 2024?: 2 brokers have issued 1 year target prices for UroGen Pharma's shares. Their URGN share price targets range from $34.00 to $54.00. On average, they predict the company's stock price to reach $46.67 in the next year. This suggests a possible upside of 241.9% from the stock's current price.
View analysts price targets for URGN or view top-rated stocks among Wall Street analysts.
How have URGN shares performed in 2024?: UroGen Pharma's stock was trading at $15.00 at the start of the year. Since then, URGN stock has decreased by 9.0% and is now trading at $13.65.
View the best growth stocks for 2024 here.
When is UroGen Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our URGN earnings forecast.
How were UroGen Pharma's earnings last quarter?: UroGen Pharma Ltd. (NASDAQ:URGN) announced its quarterly earnings data on Thursday, March, 14th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by $0.05. The firm earned $23.53 million during the quarter, compared to the consensus estimate of $22.30 million.

What ETFs hold UroGen Pharma's stock?: ETFs with the largest weight of UroGen Pharma (NASDAQ:URGN) stock in their portfolio include ARK Israel Innovative Technology ETF (IZRL).Amplify BlueStar Israel Technology ETF (ITEQ).
What other stocks do shareholders of UroGen Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioPharma (AYTU).
When did UroGen Pharma IPO?: UroGen Pharma (URGN) raised $46 million in an IPO on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.
How do I buy shares of UroGen Pharma?: Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:URGN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

UroGen Pharma (URGN) Stock Price, News & Analysis

UroGen Pharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About UroGen Pharma Stock (NASDAQ:URGN)

URGN Stock Price History

URGN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

URGN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™